SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter report and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling Lillys breakout and a wave of analyst upgrades. Traders are also weighing the growth outlook against a lower profit forecast tied to acquisition-related R&D charges, weaker-than-expected Foundayo sales and concerns about valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders weigh Middle East supply risksespecially reported attacks and threats around the Strait of Hormuzagainst possible US-Iran negotiations that could ease oil prices. Bulls cite disrupted flows and escalation risks, while bears argue that a deal or de-escalation could quickly unwind the geopolitical premium.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake is drawing attention as traders await the FDAs decision on whether to accept its sonelokimab application for hidradenitis suppurativa and what review timeline it will receive. The community is split between optimism about the drug and upcoming regulatory milestone and concern over approval risk, commercialization plans, and continued weakness in biotech shares.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs steep decline has fueled debate over its turnaround, with investors split between buying the beaten-down dividend stock and worrying about weak sales, execution and dividend sustainability. Upcoming quarterly results and the incoming CEOs ability to revive growth are also in focus.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its quarterly report, with traders weighing whether guidance can hold against concerns about its Caremark PBM business and Aetnas Medicare Advantage outlook. Some see an undervalued, defensive healthcare business, while others remain wary of the operating and reimbursement pressures.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargos Q3 results are driving attention: earnings topped expectations, but a revenue and net interest income shortfall, alongside higher loan-loss provisions, weighed on shares. Traders are split between concern over lending trends and the view that profit growth and healthy business activity remain supportive.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Schwab and thinkorswim platform outages are drawing attention, with many users reporting login problems, inaccurate quotes, and inability to place or manage trades. Frustration is widespread, and some traders say the recurring reliability issues are prompting them to consider moving to other brokerages.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is falling with semiconductor and technology stocks as Intels weak outlook and broader doubts about AI infrastructure spending and returns pressure the sector ahead of AMDs earnings. Traders debate whether the move is sympathy sellingwith some arguing Intels struggles could benefit AMDor a warning about stretched valuations and cooling AI expectations.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October deliveries rose month over month, prompting debate over whether the growth can support its ambitious fourth-quarter delivery pace. Bulls see the delivery trend as evidence of demand, while skeptics remain focused on uncertainty around guidance and the stocks prolonged decline.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStop warrants reportedly expiring worthless, with traders split over whether that removes a dilution overhang or leaves warrant holders with losses and reflects poorly on management. Speculation about Roaring Kittys changed X profile and a possible return is adding excitement, but no return is confirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim...

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss...

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA...

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company). Sarepta is a biopharmaceutical company focused on...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as a...

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec...

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima...

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG...

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Equity

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The Phase 3 HARBOR study compared the experimental drug with a dummy treatment in people with DM1, a progressive illness that stiffens and weakens muscles and has no approved medicine.</li><li>Patients did not open a clenched hand faster in a statistically meaningful way on the trial’s main measure.</li><li>The disappointment follows Friday’s failure of pelacarsen, Novartis’s late-stage heart drug licensed from Ionis Pharmaceuticals.</li></ul>Novartis shares (NVS) sold off hard on Tuesday after the company said a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second failed trial in a week.&nbsp;&nbsp;The stock closed down 14%, clocking its worst day in over 20 years.&nbsp;<h2 class="st-heading-2">Hand-Stiffness Test Falls Short</h2>The Phase 3 HARBOR study compared the experimental drug with a dummy treatment in people with DM1, a progressive illness that stiffens and weakens muscles and has no approved medicine. Patients did not open a clenched hand faster in a statistically meaningful way on the trial’s main measure. Novartis said the drug showed signs of activity on secondary measures and that safety was in line with earlier studies. The company is reviewing the full data and will talk with regulators about next steps.“Developing therapies for a complex disease like DM1 remains challenging, and setbacks are part of scientific progress,” said Shreeram Aradhye, Novartis’s president of development and chief medical officer.&nbsp;Del-desiran came into the company through its $12 billion purchase of Avidity Biosciences. Novartis said work continues on two other drugs from that deal and that its longer-term sales growth outlook is unchanged.&nbsp;<h2 class="st-heading-2">A Second Miss In One Week</h2>The disappointment follows Friday’s failure of pelacarsen, Novartis’s late-stage heart drug licensed from Ionis Pharmaceuticals. That study lowered the targeted blood fat but did not cut the risk of heart attacks, strokes and related events.&nbsp;“These are not the results we hoped for,” Aradhye said on Friday.&nbsp;<h2 class="st-heading-2">Other Stocks Slide; Analysts Split On Fallout</h2>Companies working on related muscle diseases moved with Novartis. Shares of Dyne Therapeutics (DYN), which is developing zbasivarsen for DM1, fell 16%. Sarepta Therapeutics (SRPT) was down 7%.Jefferies said the HARBOR miss “may negatively impact the space,” but argued Dyne’s zbasivarsen could still work and “even generate superior data.” The firm called Dyne the “frontrunner” in DM1 after Novartis’s failure and kept a Buy rating and $50 target.&nbsp;Stifel said many investors had treated HARBOR as likely to succeed and that Dyne will stay under pressure. The bear case, it said, is that the drugs look similar and Dyne’s pivotal study is smaller. Stifel still likes Dyne’s scientific case, would buy the selloff, and rates the stock Buy with a $37 target.&nbsp;H.C. Wainwright kept a Sell rating and $5 target on Sarepta. It said the miss is “particularly relevant” as support for Sarepta’s marketed Duchenne story has faded, and it raises the bar for Sarepta’s SRP-1003 being developed to treat DM1.&nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around NVS stock remained ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.&nbsp;A few Stocktwits users opined that Novartis should strengthen its pipeline with other buyouts.&nbsp;<stembedurl>https://stocktwits.com/CityLife511/message/663805749</stembedurl><stembedurl>https://stocktwits.com/HalfTrader/message/663812506</stembedurl>Another user called Tuesday's selloff a good opportunity and expressed hopes for a recovery.<stembedurl>https://stocktwits.com/SenefAS/message/663779750</stembedurl><a href="https://stocktwits.com/symbol/NVS">NVS stock</a> is trading flat year-to-date.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nflx-is-opening-up-box-office-numbers-for-six-upcoming-films-says-report-is-netflix-rethinking-its-movie-theater-strategy/cZtE4kpRJyR">NFLX Is Opening Up Box Office Numbers For Six Upcoming Films, Says Report — Is Netflix Rethinking Its Movie-Theater Strategy?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.

Dyne Therapeutics Inc

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.62
Prev Close	$19.23
Open	$19.04
Dividend Yield	0.00%
50-Day Moving Average	$19.24
Beta	1.31
Avg. Volume	2.94M
PE Ratio	-6.43

52-Week High	$24.68
52-Week Low	$14.68
Market Capitalization	$1.97B
EPS (Annual)	-$7.13
Price to Book	1.29
Revenue Per Employee	$2.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRPT Fundamentals